中国免疫学杂志Issue(12)：1683-1685,1691,4.DOI:10.3969/j.issn.1000-484X.2014.12.022
鞘氨醇激酶1蛋白在乳腺浸润性导管癌组织中的表达及其临床意义
Evaluation of sphingosine kinase 1 expression and its clinical significance in breast invasive ductal carcinoma
易敏 1王嵘 2陈璐 1沈婷婷 1宋连川 1种生珍1
作者信息
- 1. 青海省第五人民医院病理科，西宁 810007
- 2. 青海省第五人民医院肿瘤科，西宁810007
- 折叠
摘要
Abstract
Objective:To investigate the expression of sphingosine kinase 1 (SphK1) and its clinical significance in breast invasive ductal carcinoma ( BIDC).Methods: We detected SphK1 expression in 58 samples of surgically resected paired BIDC and normal tumor-adjacent tissues samples by using immunohistochemistry.The correlation between SphK 1 expression and clinicopathologic features was analyzed.Results: The positive expression rate of SphK 1 in BIDC tissues was 69.0% ( 40/58 ) , while its positive expression rate in normal tumor-adjacent was 17.2% (10/58),the difference was statistical significance (χ2=31.636,P=0.000). Clinicopathological evaluation suggested that SphK 1 positive expression was associated with ER negative (χ2=4.392,P=0.036),PR negative (χ2=7.920 , P=0.005 ) , lymph node metastasis (χ2 =5.033 , P=0.025 ) and tumor stage (χ2 =7.117 , P=0.008 ) . Conclusion:The high-expression of SphK1 is correlated with the poor clinicopathological features in BIDC ,suggesting SphK1 may play a key role in development and progression of BIDC.关键词
鞘氨醇激酶1/乳腺浸润性导管癌/临床意义/免疫组化染色Key words
SphK1/Breast invasive ductal carcinoma/Clinical significance/Immunohistochemistry分类
医药卫生引用本文复制引用
易敏,王嵘,陈璐,沈婷婷,宋连川,种生珍..鞘氨醇激酶1蛋白在乳腺浸润性导管癌组织中的表达及其临床意义[J].中国免疫学杂志,2014,(12):1683-1685,1691,4.
